Emergent BioSolutions (EBS) Misses Q2 EPS by 43c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.62 +2.90%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($1.06), $0.43 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $337.9 million versus the consensus estimate of $217.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
- Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
